Template:PID antibiotics - Revision history

Danbot: Add AntibioticDose entries: Azithromycin

2026-03-20T10:54:29Z

Add AntibioticDose entries: Azithromycin

← Older revision		Revision as of 10:54, 20 March 2026
Line 9:		Line 9:
	*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Clindamycin\|dose=900mg IV q8hr\|context=Inpatient alternative; combined with Gentamicin}} + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Gentamicin\|dose=2mg/kg loading then 1.5mg/kg q8hr IV\|context=Inpatient; combined with Clindamycin}} OR		*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Clindamycin\|dose=900mg IV q8hr\|context=Inpatient alternative; combined with Gentamicin}} + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Gentamicin\|dose=2mg/kg loading then 1.5mg/kg q8hr IV\|context=Inpatient; combined with Clindamycin}} OR
	*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Ampicillin/Sulbactam\|dose=3g IV q6hr\|context=Inpatient alternative; combined with Doxycycline}} + [[doxycycline]] 100mg IV/PO q12hr		*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Ampicillin/Sulbactam\|dose=3g IV q6hr\|context=Inpatient alternative; combined with Doxycycline}} + [[doxycycline]] 100mg IV/PO q12hr
			*{{AntibioticDose\|drug=Azithromycin\|dose=500mg IV q24h x1-2 days, then 250mg PO q24h x5-6 days\|context=PID\|disease=Pelvic inflammatory disease\|population=Adult}}

Danbot: Convert to AntibioticDose template for SMW integration

2026-03-20T02:24:45Z

Convert to AntibioticDose template for SMW integration

← Older revision		Revision as of 02:24, 20 March 2026
Line 1:		Line 1:
	===Antibiotics===		===Antibiotics===
	*No sexual activity for 2 weeks;		*No sexual activity for 2 weeks;
	*Treat all partners who had sex with patient during previous 60 days prior to symptom onset		*Treat all partners who had sex with patient during previous 60 days prior to symptom onset

	==== Outpatient Antibiotic Options ====		==== Outpatient Antibiotic Options ====
	*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Ceftriaxone\|dose=500mg IM x1 (1g if ~~over~~ 150kg)\|context=Outpatient~~\|population=Adult~~}}<ref>Hayes BD. Trick of the Trade: IV ceftriaxone for gonorrhea. October 9th, 2012 ALiEM. https://www.aliem.com/2012/10/trick-of-trade-iv-ceftriaxone-for/. Accessed October 23, 2018.</ref><ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm</ref> x1 + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Doxycycline\|dose=100mg PO BID x 14 days\|context=Outpatient~~\|population=Adult~~}} + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Metronidazole\|dose=500mg PO BID x 14 days\|context=Outpatient~~\|population=Adult~~}} <ref>Ness RB et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:~~929–37~~</ref><ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):~~1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>~~		*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Ceftriaxone\|dose=500mg IM x1 (1g if >150kg)\|context=Outpatient; combined with Doxycycline and Metronidazole}}<ref>Hayes BD. Trick of the Trade: IV ceftriaxone for gonorrhea. October 9th, 2012 ALiEM. https://www.aliem.com/2012/10/trick-of-trade-iv-ceftriaxone-for/. Accessed October 23, 2018.</ref><ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm</ref> + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Doxycycline\|dose=100mg PO BID x 14 days\|context=Outpatient}} + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Metronidazole\|dose=500mg PO BID x 14 days\|context=Outpatient; recommended empirically by CDC and European guidelines}}<ref>Ness RB et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929-37</ref><ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1-187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>
	**[[Metronidazole]]		*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Cefoxitin\|dose=2g IM x1 plus Probenecid 1g PO\|context=Outpatient alternative}}<ref>CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm</ref> + [[Doxycycline]] 100mg PO BID x 14 days + [[metronidazole]]
	***Recommended for empiric treatment of PID by the CDC <ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-~~4):1–187~~. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon~~</ref>~~
	***Recommended empirically by European guidelines <ref>Ross J, Guaschino S, Cusini M, Jensen J, 2017 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2018 Feb;29(2):108-114. doi: 10.1177/0956462417744099. Epub 2017 Dec 4.</ref>
	*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Cefoxitin\|dose=2g IM x1 ~~with~~ Probenecid 1g PO x1\|context=~~Alt outpatient\|population=Adult~~}}<ref>CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm</ref> + [[Doxycycline]] 100mg PO BID x 14 days + [[~~Metronidazole~~]]

	==== Inpatient Antibiotic Options ====		==== Inpatient Antibiotic Options ====
	*Recommended<ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):~~1–187~~. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>: {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Ceftriaxone\|dose=1g IV ~~q24hrs~~\|context=Inpatient~~\|population=Adult~~}} OR {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Cefoxitin\|dose=2g IV ~~q6hrs~~\|context=Inpatient~~\|population=Adult~~}} OR {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Cefotetan\|dose=2g IV ~~q12hrs~~\|context=Inpatient~~\|population=Adult~~}}) + [[Doxycycline]] 100mg PO or IV ~~q12hrs~~ + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Metronidazole\|dose=500mg IV or PO ~~q12hrs~~\|context=Inpatient~~\|population=Adult~~}} OR		*Recommended<ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1-187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>: {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Ceftriaxone\|dose=1g IV q24hr\|context=Inpatient; combined with Doxycycline and Metronidazole}} OR {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Cefoxitin\|dose=2g IV q6hr\|context=Inpatient}} OR {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Cefotetan\|dose=2g IV q12hr\|context=Inpatient}} + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Doxycycline\|dose=100mg PO or IV q12hr\|context=Inpatient}} + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Metronidazole\|dose=500mg IV or PO q12hr\|context=Inpatient}} OR
	*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Clindamycin\|dose=900mg IV ~~q8hrs~~\|context=Inpatient ~~alt\|population=Adult~~}} + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Gentamicin\|dose=2mg/kg loading then 1.5mg/kg ~~q8hrs~~ IV\|context=Inpatient ~~alt~~ with Clindamycin~~\|population=Adult~~}} OR		*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Clindamycin\|dose=900mg IV q8hr\|context=Inpatient alternative; combined with Gentamicin}} + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Gentamicin\|dose=2mg/kg loading then 1.5mg/kg q8hr IV\|context=Inpatient; combined with Clindamycin}} OR
	*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Ampicillin/Sulbactam\|dose=3g IV ~~q6hrs~~\|context=Inpatient ~~alt\|population=Adult~~}} + [[~~Doxycycline~~]] 100mg IV/PO ~~q12hrs~~		*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Ampicillin/Sulbactam\|dose=3g IV q6hr\|context=Inpatient alternative; combined with Doxycycline}} + [[doxycycline]] 100mg IV/PO q12hr

Danbot: Convert to AntibioticDose with disease=Pelvic inflammatory disease for SMW linking

2026-03-20T01:18:02Z

Convert to AntibioticDose with disease=Pelvic inflammatory disease for SMW linking

← Older revision		Revision as of 01:18, 20 March 2026
Line 4:		Line 4:

	==== Outpatient Antibiotic Options ====		==== Outpatient Antibiotic Options ====
	*[[Ceftriaxone]] 500mg IM (1g if >150kg)<ref>Hayes BD. Trick of the Trade: IV ceftriaxone for gonorrhea. October 9th, 2012 ALiEM. https://www.aliem.com/2012/10/trick-of-trade-iv-ceftriaxone-for/. Accessed October 23, 2018.</ref><ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm</ref> x1 + ~~[[doxycycline]]~~ 100mg PO BID ~~x14d~~ + ~~[[metronidazole]]~~ 500mg PO BID ~~x14d~~ <ref>Ness RB et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–37</ref><ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>		*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Ceftriaxone\|dose=500mg IM x1 (1g if over 150kg)\|context=Outpatient\|population=Adult}}<ref>Hayes BD. Trick of the Trade: IV ceftriaxone for gonorrhea. October 9th, 2012 ALiEM. https://www.aliem.com/2012/10/trick-of-trade-iv-ceftriaxone-for/. Accessed October 23, 2018.</ref><ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm</ref> x1 + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Doxycycline\|dose=100mg PO BID x 14 days\|context=Outpatient\|population=Adult}} + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Metronidazole\|dose=500mg PO BID x 14 days\|context=Outpatient\|population=Adult}} <ref>Ness RB et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–37</ref><ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>
	**[[Metronidazole]]		**[[Metronidazole]]
	***Recommended for empiric treatment of PID by the CDC <ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>		***Recommended for empiric treatment of PID by the CDC <ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>
	***Recommended empirically by European guidelines <ref>Ross J, Guaschino S, Cusini M, Jensen J, 2017 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2018 Feb;29(2):108-114. doi: 10.1177/0956462417744099. Epub 2017 Dec 4.</ref>		***Recommended empirically by European guidelines <ref>Ross J, Guaschino S, Cusini M, Jensen J, 2017 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2018 Feb;29(2):108-114. doi: 10.1177/0956462417744099. Epub 2017 Dec 4.</ref>
	*[[Cefoxitin~~]] 2 g~~ IM ~~in a single dose and~~ Probenecid~~, 1 g~~ PO ~~administered concurrently in a single dose~~<ref>CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm</ref> + [[Doxycycline]] ~~100 mg~~ PO BID x 14 days + [[~~metronidazole~~]]		*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Cefoxitin\|dose=2g IM x1 with Probenecid 1g PO x1\|context=Alt outpatient\|population=Adult}}<ref>CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm</ref> + [[Doxycycline]] 100mg PO BID x 14 days + [[Metronidazole]]

	==== Inpatient Antibiotic Options ====		==== Inpatient Antibiotic Options ====
	*Recommended<ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>: [[Ceftriaxone~~]] 1gm~~ IV ~~q24hr~~ OR [[Cefoxitin~~]] 2gm~~ IV ~~q6hr~~ OR ~~[[cefotetan]] 2gm~~ IV ~~q12hr~~) + [[~~doxycycline~~]] PO or IV ~~100 mg q12hr~~ + [[Metronidazole]] 500mg IV or PO ~~Q12hr~~ OR		*Recommended<ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>: {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Ceftriaxone\|dose=1g IV q24hrs\|context=Inpatient\|population=Adult}} OR {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Cefoxitin\|dose=2g IV q6hrs\|context=Inpatient\|population=Adult}} OR {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Cefotetan\|dose=2g IV q12hrs\|context=Inpatient\|population=Adult}}) + [[Doxycycline]] 100mg PO or IV q12hrs + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Metronidazole\|dose=500mg IV or PO q12hrs\|context=Inpatient\|population=Adult}} OR
	*[[Clindamycin]] 900mg IV ~~q8h~~ + ~~[[gentamicin]]~~ 2mg/kg loading -> 1.~~5 mg~~/kg ~~q8hr~~ IV OR		*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Clindamycin\|dose=900mg IV q8hrs\|context=Inpatient alt\|population=Adult}} + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Gentamicin\|dose=2mg/kg loading then 1.5mg/kg q8hrs IV\|context=Inpatient alt with Clindamycin\|population=Adult}} OR
	*[[Ampicillin~~-sulbactam]] 3gm~~ IV ~~q6hr~~ + [[~~doxycycline~~]] 100mg IV/PO ~~q12hr~~		*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Ampicillin/Sulbactam\|dose=3g IV q6hrs\|context=Inpatient alt\|population=Adult}} + [[Doxycycline]] 100mg IV/PO q12hrs

Athorne: /* Inpatient Antibiotic Options */

2021-07-28T17:34:12Z

Inpatient Antibiotic Options

← Older revision		Revision as of 17:34, 28 July 2021
Line 11:		Line 11:

	==== Inpatient Antibiotic Options ====		==== Inpatient Antibiotic Options ====
	*[[Cefoxitin]] 2gm IV q6hr OR [[cefotetan]] 2gm IV q12hr) + [[doxycycline]] PO or IV 100 mg q12hr OR		*Recommended<ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>: [[Ceftriaxone]] 1gm IV q24hr OR [[Cefoxitin]] 2gm IV q6hr OR [[cefotetan]] 2gm IV q12hr) + [[doxycycline]] PO or IV 100 mg q12hr + [[Metronidazole]] 500mg IV or PO Q12hr OR
	*[[Clindamycin]] 900mg IV q8h + [[gentamicin]] 2mg/kg QD OR		*[[Clindamycin]] 900mg IV q8h + [[gentamicin]] 2mg/kg loading -> 1.5 mg/kg q8hr IV OR
	*[[Ampicillin-sulbactam]] 3gm IV q6hr + [[doxycycline]] 100mg IV/PO q12hr		*[[Ampicillin-sulbactam]] 3gm IV q6hr + [[doxycycline]] 100mg IV/PO q12hr

Athorne: /* Outpatient Antibiotic Options */

2021-07-28T17:29:56Z

Outpatient Antibiotic Options

← Older revision		Revision as of 17:29, 28 July 2021
Line 6:		Line 6:
	*[[Ceftriaxone]] 500mg IM (1g if >150kg)<ref>Hayes BD. Trick of the Trade: IV ceftriaxone for gonorrhea. October 9th, 2012 ALiEM. https://www.aliem.com/2012/10/trick-of-trade-iv-ceftriaxone-for/. Accessed October 23, 2018.</ref><ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm</ref> x1 + [[doxycycline]] 100mg PO BID x14d + [[metronidazole]] 500mg PO BID x14d <ref>Ness RB et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–37</ref><ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>		*[[Ceftriaxone]] 500mg IM (1g if >150kg)<ref>Hayes BD. Trick of the Trade: IV ceftriaxone for gonorrhea. October 9th, 2012 ALiEM. https://www.aliem.com/2012/10/trick-of-trade-iv-ceftriaxone-for/. Accessed October 23, 2018.</ref><ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm</ref> x1 + [[doxycycline]] 100mg PO BID x14d + [[metronidazole]] 500mg PO BID x14d <ref>Ness RB et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–37</ref><ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>
	**[[Metronidazole]]		**[[Metronidazole]]
	***~~Newly~~ Recommended for empiric treatment of PID by the CDC <ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>		***Recommended for empiric treatment of PID by the CDC <ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>
	***Recommended empirically by European guidelines <ref>Ross J, Guaschino S, Cusini M, Jensen J, 2017 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2018 Feb;29(2):108-114. doi: 10.1177/0956462417744099. Epub 2017 Dec 4.</ref>		***Recommended empirically by European guidelines <ref>Ross J, Guaschino S, Cusini M, Jensen J, 2017 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2018 Feb;29(2):108-114. doi: 10.1177/0956462417744099. Epub 2017 Dec 4.</ref>
	*[[Cefoxitin]] 2 g IM in a single dose and Probenecid, 1 g PO administered concurrently in a single dose<ref>CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm</ref> + [[Doxycycline]] 100 mg PO BID x 14 days + [[metronidazole]]		*[[Cefoxitin]] 2 g IM in a single dose and Probenecid, 1 g PO administered concurrently in a single dose<ref>CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm</ref> + [[Doxycycline]] 100 mg PO BID x 14 days + [[metronidazole]]

Athorne: /* Outpatient Antibiotic Options */

2021-07-28T17:29:03Z

Outpatient Antibiotic Options

← Older revision		Revision as of 17:29, 28 July 2021
Line 4:		Line 4:

	==== Outpatient Antibiotic Options ====		==== Outpatient Antibiotic Options ====
	*[[Ceftriaxone]] 500mg IM (~~or IV~~)<ref>Hayes BD. Trick of the Trade: IV ceftriaxone for gonorrhea. October 9th, 2012 ALiEM. https://www.aliem.com/2012/10/trick-of-trade-iv-ceftriaxone-for/. Accessed October 23, 2018.</ref><ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm</ref> x1 + [[doxycycline]] 100mg PO BID x14d +/- [[metronidazole]] 500mg PO BID x14d <ref>Ness RB et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–37</ref>		*[[Ceftriaxone]] 500mg IM (1g if >150kg)<ref>Hayes BD. Trick of the Trade: IV ceftriaxone for gonorrhea. October 9th, 2012 ALiEM. https://www.aliem.com/2012/10/trick-of-trade-iv-ceftriaxone-for/. Accessed October 23, 2018.</ref><ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm</ref> x1 + [[doxycycline]] 100mg PO BID x14d + [[metronidazole]] 500mg PO BID x14d <ref>Ness RB et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–37</ref><ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>
	**[[Metronidazole]]		**[[Metronidazole]]
			***Newly Recommended for empiric treatment of PID by the CDC <ref>Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(No. RR-4):1–187. DOI: http://dx.doi.org/10.15585/mmwr.rr7004a1external icon</ref>
	***Recommended empirically by European guidelines <ref>Ross J, Guaschino S, Cusini M, Jensen J, 2017 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2018 Feb;29(2):108-114. doi: 10.1177/0956462417744099. Epub 2017 Dec 4.</ref>		***Recommended empirically by European guidelines <ref>Ross J, Guaschino S, Cusini M, Jensen J, 2017 European guideline for the management of pelvic inflammatory disease. Int J STD AIDS. 2018 Feb;29(2):108-114. doi: 10.1177/0956462417744099. Epub 2017 Dec 4.</ref>
	***American guidelines based upon assessment of risk for [[anaerobes]]; consider in:		*[[Cefoxitin]] 2 g IM in a single dose and Probenecid, 1 g PO administered concurrently in a single dose<ref>CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm</ref> + [[Doxycycline]] 100 mg PO BID x 14 days + [[metronidazole]]
	****Pelvic abscess
	****Proven or suspected infection w/ [[Trichomonas]] or [[Bacterial Vaginosis]]
	****History of gynecological instrumentation in the preceding 2-3wks
	*[[Cefoxitin]] 2 g IM in a single dose and Probenecid, 1 g PO administered concurrently in a single dose<ref>CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm</ref> + [[Doxycycline]] 100 mg PO BID x 14 days +/- [[~~flagyl~~]] ~~based on above criteria~~

	==== Inpatient Antibiotic Options ====		==== Inpatient Antibiotic Options ====

Rossdonaldson1: /* Discontinued */

2021-05-27T16:55:20Z

Discontinued

← Older revision		Revision as of 16:55, 27 May 2021
Line 12:		Line 12:
	****History of gynecological instrumentation in the preceding 2-3wks		****History of gynecological instrumentation in the preceding 2-3wks
	*[[Cefoxitin]] 2 g IM in a single dose and Probenecid, 1 g PO administered concurrently in a single dose<ref>CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm</ref> + [[Doxycycline]] 100 mg PO BID x 14 days +/- [[flagyl]] based on above criteria		*[[Cefoxitin]] 2 g IM in a single dose and Probenecid, 1 g PO administered concurrently in a single dose<ref>CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm</ref> + [[Doxycycline]] 100 mg PO BID x 14 days +/- [[flagyl]] based on above criteria

	~~=====Discontinued=====~~
	*Historically the following regimens were acceptable but with the emerging resistance patterns use the following with caution.<ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm </ref>
	*[[Ceftriaxone]] 250mg IM x1 + 1 g of [[azithromycin]] per week, x 2 weeks<ref name="Savaris">Savaris RF. et al. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstet Gynecol. 2007 Jul;110(1):53-60</ref> +/- [[metronidazole]] based on above criteria
	**A single randomized controlled trial shows that [[azithromycin]] is superior to [[doxycycline]] even when compliance in taking doxycycline is excellent (98.2% vs 87.5%)<ref name="Savaris"></ref>

	==== Inpatient Antibiotic Options ====		==== Inpatient Antibiotic Options ====

Rossdonaldson1: /* Antibiotics */

2021-05-27T16:52:36Z

Antibiotics

← Older revision		Revision as of 16:52, 27 May 2021
Line 1:		Line 1:
	===Antibiotics===		===Antibiotics===
	;No sexual activity for 2 weeks;		*No sexual activity for 2 weeks;
	;Treat all partners who had sex with patient during previous 60 days prior to symptom onset		*Treat all partners who had sex with patient during previous 60 days prior to symptom onset

	==== Outpatient Antibiotic Options ====		==== Outpatient Antibiotic Options ====

Rossdonaldson1 at 16:50, 27 May 2021

2021-05-27T16:50:04Z

Rossdonaldson1 at 16:42, 27 May 2021

2021-05-27T16:42:58Z

← Older revision		Revision as of 16:42, 27 May 2021
Line 2:		Line 2:
	;Treat all partners who had sex with patient during previous 60 days prior to symptom onset		;Treat all partners who had sex with patient during previous 60 days prior to symptom onset

	=== Outpatient Options ===		=== Outpatient Antibiotic Options ===
	*[[Ceftriaxone]] 500mg IM (or IV)<ref>Hayes BD. Trick of the Trade: IV ceftriaxone for gonorrhea. October 9th, 2012 ALiEM. https://www.aliem.com/2012/10/trick-of-trade-iv-ceftriaxone-for/. Accessed October 23, 2018.</ref><ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm</ref> x1 + [[doxycycline]] 100mg PO BID x14d +/- [[metronidazole]] 500mg PO BID x14d <ref>Ness RB et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–37</ref>		*[[Ceftriaxone]] 500mg IM (or IV)<ref>Hayes BD. Trick of the Trade: IV ceftriaxone for gonorrhea. October 9th, 2012 ALiEM. https://www.aliem.com/2012/10/trick-of-trade-iv-ceftriaxone-for/. Accessed October 23, 2018.</ref><ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm</ref> x1 + [[doxycycline]] 100mg PO BID x14d +/- [[metronidazole]] 500mg PO BID x14d <ref>Ness RB et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–37</ref>
	**[[Metronidazole]]		**[[Metronidazole]]
Line 12:		Line 12:
	*[[Cefoxitin]] 2 g IM in a single dose and Probenecid, 1 g PO administered concurrently in a single dose<ref>CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm</ref> + [[Doxycycline]] 100 mg PO BID x 14 days +/- [[flagyl]] based on above criteria		*[[Cefoxitin]] 2 g IM in a single dose and Probenecid, 1 g PO administered concurrently in a single dose<ref>CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm</ref> + [[Doxycycline]] 100 mg PO BID x 14 days +/- [[flagyl]] based on above criteria

	====Discontinued ~~Outpatient Options~~====		====Discontinued====
	*Historically the following regimens were acceptable but with the emerging resistance patterns use the following with caution.<ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm </ref>		*Historically the following regimens were acceptable but with the emerging resistance patterns use the following with caution.<ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm </ref>
	*[[Ceftriaxone]] 250mg IM x1 + 1 g of [[azithromycin]] per week, x 2 weeks<ref name="Savaris">Savaris RF. et al. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstet Gynecol. 2007 Jul;110(1):53-60</ref> +/- [[metronidazole]] based on above criteria		*[[Ceftriaxone]] 250mg IM x1 + 1 g of [[azithromycin]] per week, x 2 weeks<ref name="Savaris">Savaris RF. et al. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstet Gynecol. 2007 Jul;110(1):53-60</ref> +/- [[metronidazole]] based on above criteria
	**A single randomized controlled trial shows that [[azithromycin]] is superior to [[doxycycline]] even when compliance in taking doxycycline is excellent (98.2% vs 87.5%)<ref name="Savaris"></ref>		**A single randomized controlled trial shows that [[azithromycin]] is superior to [[doxycycline]] even when compliance in taking doxycycline is excellent (98.2% vs 87.5%)<ref name="Savaris"></ref>

	=== Inpatient ===		=== Inpatient Antibiotic Options ===
	*[[Cefoxitin]] 2gm IV q6hr OR [[cefotetan]] 2gm IV q12hr) + [[doxycycline]] PO or IV 100 mg q12hr OR		*[[Cefoxitin]] 2gm IV q6hr OR [[cefotetan]] 2gm IV q12hr) + [[doxycycline]] PO or IV 100 mg q12hr OR
	*[[Clindamycin]] 900mg IV q8h + [[gentamicin]] 2mg/kg QD OR		*[[Clindamycin]] 900mg IV q8h + [[gentamicin]] 2mg/kg QD OR
	*[[Ampicillin-sulbactam]] 3gm IV q6hr + [[doxycycline]] 100mg IV/PO q12hr		*[[Ampicillin-sulbactam]] 3gm IV q6hr + [[doxycycline]] 100mg IV/PO q12hr

← Older revision		Revision as of 10:54, 20 March 2026
Line 9:		Line 9:
	*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Clindamycin\|dose=900mg IV q8hr\|context=Inpatient alternative; combined with Gentamicin}} + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Gentamicin\|dose=2mg/kg loading then 1.5mg/kg q8hr IV\|context=Inpatient; combined with Clindamycin}} OR		*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Clindamycin\|dose=900mg IV q8hr\|context=Inpatient alternative; combined with Gentamicin}} + {{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Gentamicin\|dose=2mg/kg loading then 1.5mg/kg q8hr IV\|context=Inpatient; combined with Clindamycin}} OR
	*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Ampicillin/Sulbactam\|dose=3g IV q6hr\|context=Inpatient alternative; combined with Doxycycline}} + [[doxycycline]] 100mg IV/PO q12hr		*{{AntibioticDose\|disease=Pelvic inflammatory disease\|drug=Ampicillin/Sulbactam\|dose=3g IV q6hr\|context=Inpatient alternative; combined with Doxycycline}} + [[doxycycline]] 100mg IV/PO q12hr
			*{{AntibioticDose\|drug=Azithromycin\|dose=500mg IV q24h x1-2 days, then 250mg PO q24h x5-6 days\|context=PID\|disease=Pelvic inflammatory disease\|population=Adult}}

← Older revision		Revision as of 16:50, 27 May 2021
Line 1:		Line 1:
			===Antibiotics===
	;No sexual activity for 2 weeks;		;No sexual activity for 2 weeks;
	;Treat all partners who had sex with patient during previous 60 days prior to symptom onset		;Treat all partners who had sex with patient during previous 60 days prior to symptom onset

	=== Outpatient Antibiotic Options ===		==== Outpatient Antibiotic Options ====
	*[[Ceftriaxone]] 500mg IM (or IV)<ref>Hayes BD. Trick of the Trade: IV ceftriaxone for gonorrhea. October 9th, 2012 ALiEM. https://www.aliem.com/2012/10/trick-of-trade-iv-ceftriaxone-for/. Accessed October 23, 2018.</ref><ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm</ref> x1 + [[doxycycline]] 100mg PO BID x14d +/- [[metronidazole]] 500mg PO BID x14d <ref>Ness RB et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–37</ref>		*[[Ceftriaxone]] 500mg IM (or IV)<ref>Hayes BD. Trick of the Trade: IV ceftriaxone for gonorrhea. October 9th, 2012 ALiEM. https://www.aliem.com/2012/10/trick-of-trade-iv-ceftriaxone-for/. Accessed October 23, 2018.</ref><ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm</ref> x1 + [[doxycycline]] 100mg PO BID x14d +/- [[metronidazole]] 500mg PO BID x14d <ref>Ness RB et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929–37</ref>
	**[[Metronidazole]]		**[[Metronidazole]]
Line 12:		Line 13:
	*[[Cefoxitin]] 2 g IM in a single dose and Probenecid, 1 g PO administered concurrently in a single dose<ref>CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm</ref> + [[Doxycycline]] 100 mg PO BID x 14 days +/- [[flagyl]] based on above criteria		*[[Cefoxitin]] 2 g IM in a single dose and Probenecid, 1 g PO administered concurrently in a single dose<ref>CDC PID Treatment http://www.cdc.gov/std/treatment/2010/pid.htm</ref> + [[Doxycycline]] 100 mg PO BID x 14 days +/- [[flagyl]] based on above criteria

	====Discontinued====		=====Discontinued=====
	*Historically the following regimens were acceptable but with the emerging resistance patterns use the following with caution.<ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm </ref>		*Historically the following regimens were acceptable but with the emerging resistance patterns use the following with caution.<ref>Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020 https://www.cdc.gov/mmwr/volumes/69/wr/mm6950a6.htm </ref>
	*[[Ceftriaxone]] 250mg IM x1 + 1 g of [[azithromycin]] per week, x 2 weeks<ref name="Savaris">Savaris RF. et al. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstet Gynecol. 2007 Jul;110(1):53-60</ref> +/- [[metronidazole]] based on above criteria		*[[Ceftriaxone]] 250mg IM x1 + 1 g of [[azithromycin]] per week, x 2 weeks<ref name="Savaris">Savaris RF. et al. Comparing ceftriaxone plus azithromycin or doxycycline for pelvic inflammatory disease: a randomized controlled trial. Obstet Gynecol. 2007 Jul;110(1):53-60</ref> +/- [[metronidazole]] based on above criteria
	**A single randomized controlled trial shows that [[azithromycin]] is superior to [[doxycycline]] even when compliance in taking doxycycline is excellent (98.2% vs 87.5%)<ref name="Savaris"></ref>		**A single randomized controlled trial shows that [[azithromycin]] is superior to [[doxycycline]] even when compliance in taking doxycycline is excellent (98.2% vs 87.5%)<ref name="Savaris"></ref>

	=== Inpatient Antibiotic Options ===		==== Inpatient Antibiotic Options ====
	*[[Cefoxitin]] 2gm IV q6hr OR [[cefotetan]] 2gm IV q12hr) + [[doxycycline]] PO or IV 100 mg q12hr OR		*[[Cefoxitin]] 2gm IV q6hr OR [[cefotetan]] 2gm IV q12hr) + [[doxycycline]] PO or IV 100 mg q12hr OR
	*[[Clindamycin]] 900mg IV q8h + [[gentamicin]] 2mg/kg QD OR		*[[Clindamycin]] 900mg IV q8h + [[gentamicin]] 2mg/kg QD OR
	*[[Ampicillin-sulbactam]] 3gm IV q6hr + [[doxycycline]] 100mg IV/PO q12hr		*[[Ampicillin-sulbactam]] 3gm IV q6hr + [[doxycycline]] 100mg IV/PO q12hr